Lipid reduction in acute coronary syndrome: how much, when, and how?
The use of statins for secondary prevention after acute coronary syndrome is well established. In recent years, trials have investigated the dose of statins used and timing of administration. Initiation of statin therapy as early as 1 day after an acute coronary syndrome event has been shown to be effective in reducing major adverse cardiovascular events. The benefit of early statin use is linked to reduction in inflammation and increased compliance with therapy. In addition, intensive therapy further reduces events and inflammation, as reflected by decreased C-reactive protein. Given the findings of these recent studies, early and intensive lipid-lowering therapy with a statin is justified and safe.
Jacob
Miriam
M
Women's Cardiovascular Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
Cho
Leslie
L
D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000517:prevention & control*; D000069059:Atorvastatin; D006538:Heptanoic Acids / Q000008:administration & dosage; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D015201:Meta-Analysis as Topic; D011758:Pyrroles / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D055502:Secondary Prevention / Q000379:methods; D019821:Simvastatin / Q000008:administration & dosage
D006538:Heptanoic Acids; D000960:Hypolipidemic Agents; D011758:Pyrroles; D000069059:Atorvastatin; D019821:Simvastatin